guest ::
| Home > Publications database > Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences > print |
| Home > Publications database > Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences > print |
| 001 | 890281 | ||
| 005 | 20210628150953.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.120.248278 |2 doi |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a 2128/27586 |2 Handle |
| 024 | 7 | _ | |a altmetric:89585646 |2 altmetric |
| 024 | 7 | _ | |a 32887757 |2 pmid |
| 024 | 7 | _ | |a WOS:000658416500008 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-00862 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 0 |e Corresponding author |u fzj |
| 245 | _ | _ | |a Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences |
| 260 | _ | _ | |a New York, NY |c 2021 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1618298138_12586 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive. Methods: We retrospectively identified 40 patients with 107 BMs secondary to melanoma (n = 29 with 75 BMs) or non–small cell lung cancer (n = 11 with 32 BMs) treated with ICI or TT who had 18F-FET PET (n = 60 scans) for treatment monitoring from 2015 to 2019. Most patients (n = 37; 92.5%) had radiotherapy during the course of the disease. In 27 patients, 18F-FET PET was used to differentiate treatment-related changes from BM relapse after ICI or TT. In 13 patients, 18F-FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median time between scans, 4.2 mo). In all lesions, static and dynamic 18F-FET PET parameters were obtained (i.e., mean tumor-to-brain ratios [TBR], time-to-peak values). Diagnostic accuracies of PET parameters were evaluated by receiver-operating-characteristic analyses using the clinical follow-up or neuropathologic findings as a reference. Results: A TBR threshold of 1.95 differentiated BM relapse from treatment-related changes with an accuracy of 85% (P = 0.003). Metabolic responders to ICI or TT on 18F-FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseline, ≥10%; accuracy, 82%; P = 0.004). Furthermore, at follow-up, time to peak in metabolic responders increased significantly (P = 0.019). Conclusion: 18F-FET PET may add valuable information for treatment monitoring in BM patients treated with ICI or TT. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Abdulla, Diana SY |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Scheffler, Matthias |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Wolpert, Fabian |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Huellner, Martin W |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Stoffels, Gabriele |0 P:(DE-Juel1)131627 |b 6 |u fzj |
| 700 | 1 | _ | |a Schweinsberg, Viola |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Schlaak, Max |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Kreuzberg, Nicole |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Landsberg, Jennifer |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Lohmann, Philipp |0 P:(DE-Juel1)145110 |b 11 |u fzj |
| 700 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Baues, Christian |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Trommer, Maike |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Celik, Eren |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Ruge, Maximilian I |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Kocher, Martin |0 P:(DE-Juel1)173675 |b 17 |u fzj |
| 700 | 1 | _ | |a Marnitz, Simone |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Fink, Gereon R |0 P:(DE-Juel1)131720 |b 19 |u fzj |
| 700 | 1 | _ | |a Tonn, Joerg-Christian |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Weller, Michael |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 22 |u fzj |
| 700 | 1 | _ | |a Wolf, Jürgen |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Mauch, Cornelia |0 P:(DE-HGF)0 |b 24 |
| 773 | _ | _ | |a 10.2967/jnumed.120.248278 |g p. jnumed.120.248278 - |0 PERI:(DE-600)2040222-3 |n 4 |p 464-470 |t Journal of nuclear medicine |v 62 |y 2021 |x 2159-662X |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/890281/files/Galldiks_2020_Post%20Print_JNUMED_Treatment%20monitoring%20of%20immunotherapy%20and%20targeted%20therapy.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:890281 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)143792 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131627 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)145110 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 17 |6 P:(DE-Juel1)173675 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 19 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 22 |6 P:(DE-Juel1)131777 |
| 913 | 0 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-500 |4 G:(DE-HGF)POF |v (Dys-)function and Plasticity |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-08-31 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2018 |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-08-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-31 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2018 |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-08-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-08-31 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|